Meeting Coverage:

American Society of Retina Specialists Annual Meeting

ASRS: 2018

Head-to-Head Comparison for nAMD Treatment

Show Description +

Arshad M. Khanani, MD, reviews the HAWK/HARRIER phase 3 studies on the efficacy and safety of brolucizumab (RTH258, Novartis) versus aflibercept (Eylea, Regeneron) in the treatment of neovascular age-related macular degeneration (nAMD).

Posted: 7/20/2018

Head-to-Head Comparison for nAMD Treatment

Arshad M. Khanani, MD, reviews the HAWK/HARRIER phase 3 studies on the efficacy and safety of brolucizumab (RTH258, Novartis) versus aflibercept (Eylea, Regeneron) in the treatment of neovascular age-related macular degeneration (nAMD).

Posted: 7/20/2018


Please log in to leave a comment.